August 2026– date –
-
Transforming Cell Therapy: New Report Projects Shift to Cost-Effective Manufacturing by 2035
Roots Analysis India Overview A new report from Roots Analysis, 'Cell Therapy Manufacturing Market 2035,' predicts a critical shift towards more standardized, reproducible, and cost-effective production models. This transformation is dri... -
Off-the-Shelf CAR T Therapies Revolutionize Cancer Treatment: Simplifying Manufacturing with Healthy Donor Cells, Reducing Wait Times and Costs
Katie Couric Media USA Overview Next-generation allogeneic CAR T-cell therapy, or 'off-the-shelf CAR T,' utilizes healthy donor cells instead of patient-specific cells, enabling large-batch manufacturing and extended storage. This signif... -
Early Manufacturing Planning Critical for Commercial Success of Advanced Therapies: Ensuring Scalability from Process Design to Automation
The Medicine Maker International Overview The commercial success of advanced therapies heavily depends on meticulous manufacturing planning from the early development stages. Sponsors must assess process consistency, effective technology... -
Patient-Specific iPSCs in Organ-on-a-Chip Systems: Pioneering Personalized Medicine and Drug Testing
PMC International Overview Organ-on-a-chip (OoC) systems innovatively mimic human organ structures and functions at a micro-scale. Induced pluripotent stem cells (iPSCs) serve as an ideal platform for constructing patient-specific OoC mo... -
In Vivo CAR-T Cell Therapy Demonstrates Clinical Proof-of-Concept with AI Acceleration: Enabling Direct In-Body Immune Cell Gene Editing Towards ‘Off-the-Shelf Biologics’
OncoDaily International Overview While autologous CAR-T cell therapy yields durable remissions in B-cell malignancies, its delivery model faces persistent challenges. In vivo CAR-T emerges as a radically different approach, delivering CA... -
Kyoto University iPSC Research Foundation Opens ‘Yanai my iPS Manufacturing Facility’ to Massively Enhance Clinical-Grade Autologous iPSC Production in Japan
BigGo Finance Japan Overview In 2025, with a substantial investment from Uniqlo founder Tadashi Yanai, the Kyoto University iPSC Research Foundation officially opened the 'Yanai my iPS Manufacturing Facility.' This marks Japan's first cl... -
Chinese Scientists Achieve Breakthrough: Mass Production of 14 Million NK Immune Cells from a Single Stem Cell, Paving Way for ‘Off-the-Shelf’ Immunotherapy
Facebook (referencing a February 2026 breakthrough in China) China Overview In February 2026, Chinese scientists announced a breakthrough, successfully mass-producing an astounding 14 million natural killer (NK) immune cells in the lab f... -
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
INFORMA Database Analysis Reveals Rapid Growth of Allogeneic NK Cell Immunotherapy, CAR-Engineered NK Cells Transitioning to Standardized Platforms
INFORMA database (journal article) International Overview Natural killer (NK) cell-based immunotherapy is gaining increasing prominence as a cancer treatment strategy due to its inherent cytotoxicity, allogeneic potential, and compatibil... -
Liv Hospital Charts Course for Scalable CAR-T Production with Comprehensive GMP and Bioreactor Guide
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive guide detailing the critical, GMP-compliant manufacturing process for CAR-T cell therapies, from T-cell collection and genetic modification to controlled expansion in...
